Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: SFC-IgG-seq on IBD subjects and healthy controls to quantify anti-microbiota IgG titers

PROVIDER: PRJNA820056 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18490301_1.fastq.gz	Fastqsanger.gz
	SRR18490301_2.fastq.gz	Fastqsanger.gz
	SRR18490302_1.fastq.gz	Fastqsanger.gz
	SRR18490302_2.fastq.gz	Fastqsanger.gz
	SRR18490303_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 178

Similar Datasets

RNA-seq of organoid derived monolayers (inflamed and non-inflamed) of UC patients and non-IBD controls, stimulated with microbiota of patients or a healthy donor

Project description:Dysbiosis is linked to the pathogenesis of inflammatory bowel disease. Although there is a lot of interest in restoring the balance, we do not understand the effects of dysbiosis, especially on epithelial cells. In addition, we know that epithelial cells from IBD patients maintain intrinsic defects. For that reason, we aimed to unravel if epithelial cells of UC patients are more sensitive towards microbiota stimulation, compared to non-IBD controls. In addition, we analyzed the effect of UC microbiota or microbiota of healthy donors towards epithelial cells. Confluent organoid derived monolayers of 8 UC patients and 8 non-IBD controls were co-cultured for 6 hours with microbiota (3.10^8 cells) , derived of a healthy donor (HD) or UC patients. If applicable, epithelial cells were first cultured for 24 hours with an inflammatory mix (100 ng/mL TNFα, 20 ng/mL IL1β, 1 µg/mL Flagellin). The inflammatory stimulation was continued in the 6 hours co-culture.Transcriptomic expression of epithelial cells was evaluated after 6 hours co-culture by Truseq for Illumina.

2022-07-31 | E-MTAB-10832 | biostudies-arrayexpress

Metagenomic sequencing of gut microbiota associated with autism spectrum disorders patients

Project description:Here we report metagenomic sequencing data in gut microbiota of autism spectrum disorders (ASD) compared with healthy volunteers (30 for ASD children and 30 for healthy controls, respectively). The genes changed in autistic subjects involved 1,312,364 analytes that compare to 1,335,835 analytes in healthy controls. The number of taxa in autistic subjects were significantly increased as compared to the healthy controls based on the phylum and genus level (P = 0.001). However, the number of species were significantly decreased in autistic subjects (P = 0.001).

2020-09-30 | GSE113540 | GEO

scRNAseq from pbmc, ileum, and rectal tissue of healthy and crohns disease individuals

Project description:Crohn’s disease (CD) is a major subtype of inflammatory bowel disease (IBD), a spectrum of chronic intestinal disorders caused by dysregulated immune responses to gut microbiota. We performed Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITEseq) on peripheral blood, colon, and ileal immune cells derived from healthy subjects and patients with Crohn’s disease.

2025-05-22 | GSE226039 | GEO

Impaired innate and adaptive immune responses to BNT162b2 SARSCoV-2 vaccination in systemic lupus erythematosus [CTD]

Project description:We measued IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in SLE and healthy controls who received the BNT162b2 vaccine.

2024-03-02 | GSE260478 | GEO

Impaired innate and adaptive immune responses to BNT162b2 SARSCoV-2 vaccination in systemic lupus erythematosus [ACA]

2024-03-02 | GSE260475 | GEO

Anti-inflammatory Effects of the Commensal Bacterium Faecalibacterium prausnitzii analyzed by microarrays

Project description:The human intestinal microbiota plays an essential role in host health. Modifications in its composition and diversity could induce pathologies such as inflammatory bowel diseases (IBD). These diseases are characterized by an unbalanced intestinal microbiota (a process known as dysbiosis) and an altered immune response. Faecalibacterium prausnitzii, the most abundant commensal bacterium in the human intestinal microbiota of healthy individuals (representing more than 5% of the total bacterial population), has been reported to be lower in feces and mucosa-associated microbiota of IBD patients. In addition, we have shown that both F. prausnitzii and its culture supernatant (SN) have anti-inflammatory and protective effects in both acute and chronic colitis models. However, the host molecular mechanisms involved in these anti-inflammatory effects remain unknown. In order to address this issue, we performed DNA chip-based transcriptomic analyses in HT-29 human intestinal epithelial cells stimulated with TNF-a and exposed to F. prausnitzii SN or to BHI (growth medium for F prausnitzii).

2020-11-02 | GSE72048 | GEO

Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.

Project description:Interventions: arm1: The right peptides (up to 4 peptides) for vaccination to individual patients will be selected in consideration of the pre-existing host immunity assessed by the titers of anti-peptide IgG before vaccination, and subcutaneously injected with incomplete Freund’s adjuvant every week (3.0 mg/each peptide; 6 times/cycle). Dai-kenchu-to(5 g/time, 3 times/day) will be orally administered from the date of the first vaccination to the date of the sixth vaccination. If the patients want to continue the vaccination after completion of the first cycle of 6 vaccinations, the peptide vaccination will be allowed to continue (every 2-4 weeks). arm2: The right peptides (up to 4 peptides) for vaccination to individual patients will be selected in consideration of the pre-existing host immunity assessed by the titers of anti-peptide IgG before vaccination, and subcutaneously injected with incomplete Freund’s adjuvant every week (3.0 mg/each peptide; 6 times/cycle). If the patients want to continue the vaccination after completion of the first cycle of 6 vaccinations, the peptide vaccination will be allowed to continue (every 2-4 weeks). Primary outcome(s): Comparison of immune-enhancing effects (changes in anti-peptide IgG titers in plasma)between two groups. Study Design: Parallel Randomized

| 2623536 | ecrin-mdr-crc

Common Connective Tissue Disorder and Anti-Cytokine Autoantibodies are Enriched in Idiopathic Multicentric Castleman Disease Patients [Protein Fragment Array]

Project description:We measued IgG autoantibodies associated with Connective Tissue Diseases (CTDs) and Anti-Cytokine Antibodies (ACA) in idiopathic Multicentric Castleman Disease (iMCD) patients and healthy controls who received the BNT162b2 vaccine.

2025-02-26 | GSE290594 | GEO

Common Connective Tissue Disorder and Anti-Cytokine Autoantibodies are Enriched in Idiopathic Multicentric Castleman Disease Patients [CTD Array version 3]

2025-02-26 | GSE290549 | GEO

Common Connective Tissue Disorder and Anti-Cytokine Autoantibodies are Enriched in Idiopathic Multicentric Castleman Disease Patients [CTD array version prototype]

2025-02-26 | GSE290532 | GEO